Drugs

, Volume 46, Issue 6, pp 1025–1054 | Cite as

Acarbose

An Update of its Pharmacology and Therapeutic Use in Diabetes Mellitus
  • Julia A. Balfour
  • Donna McTavish
Deug Evaluation

Abstract

Synopsis

Acarbose delays digestion of complex carbohydrates and disaccharides to absorbable monosaccharides, by reversibly inhibiting α-glucosidases within the intestinal brush border, thereby attenuating postprandial blood glucose peaks.

Clinical trials have demonstrated that acarbose generally improves glycaemic control in patients with non-insulin-dependent diabetes mellitus (NIDDM) managed with diet alone, or with other antidiabetic therapy, as evidenced by decreased postprandial plasma glucose and glycosylated haemoglobin levels. It does not appear to directly alter insulin resistance, but may lower postprandial plasma insulin levels. Fasting plasma glucose, triglyceride and/or cholesterol levels may also be decreased. Acarbose also improved metabolic control in patients with insulin-dependent diabetes mellitus (IDDM), frequently decreasing insulin requirements, although further studies are required in this indication.

Improved metabolic control appears to delay or prevent long term vascular complications of diabetes, and indeed, acarbose appeared to inhibit development of such complications in preliminary animal studies, but this finding requires confirmation in clinical studies.

While acarbose seldom causes systemic adverse effects, it is associated with a high incidence of gastrointestinal disturbances such as flatulence, abdominal distension, borborygmus and diarrhoea, caused by fermentation of unabsorbed carbohydrates. However, these symptoms tend to subside with continued treatment and adherence to an appropriate diet.

Thus, acarbose appears to be a worthwhile adjunctive therapeutic option for patients with NIDDM inadequately managed by diet alone, or with pharmacological therapy, and possibly also for patients with IDDM. However, further long term efficacy and tolerability data are required, particularly in the latter indication.

Pharmacological Properties

Acarbose is an oligosaccharide which reversibly inhibits intestinal α-glucosidase enzymes responsible for digestion of complex carbohydrates and disaccharides to absorbable monosaccharides. Thus, acarbose delays postprandial absorption of glucose, resulting in attenuation of postprandial plasma glucose, insulin and triglyceride peaks in healthy volunteers. The beneficial effects of acarbose on postprandial glucose levels have been confirmed in patients with insulin-dependent or non-insulin-dependent diabetes mellitus (IDDM or NIDDM), whereas postprandial insulin and triglyceride levels were only occasionally lowered. Pooled data from several clinical trials indicate that acarbose lowers postprandial and fasting blood glucose levels in patients with NIDDM by approximately 20 and 10%, respectively, the latter presumably by an indirect mechanism. Acarbose does not appear to exert any direct effect on insulin resistance in humans.

By decreasing the hyperglycaemic stimulus to insulin secretion, acarbose attenuates the blood glucose nadir and associated clinical symptoms which occur after carbohydrate ingestion in patients with reactive hypoglycaemia.

Delayed carbohydrate digestion increases the amount of fermentable carbohydrate in the bowel, which does not appear to cause calorie loss, because of metabolism to other absorbable nutrients by colonic microflora, but can induce gastrointestinal adverse effects such as flatulence and borborygmi. Acarbose decreases the postprandial gastric inhibitory polypeptide response, while increasing the enteroglucagon response, and also decreases intestinal absorption of iron. It does not generally appear to lower bodyweight in humans, although this effect has consistently been demonstrated in animal models.

Acarbose decreases serum triglycerides, cholesterol and free fatty acid levels in animal models of diabetes and/or hyperlipidaemia, but in human studies in diabetic and nondiabetic individuals, does not consistently lower fasting plasma triglycerides and produces only occasional decreases in fasting plasma cholesterol.

The Diabetes Control and Complications Trial (DCCT) has demonstrated that optimal control of blood glucose levels can retard long term complications of diabetes. Indeed, acarbose decreases levels of glycosylated haemoglobin in patients with diabetes, and glycosylation of other body proteins in preliminary animal studies. Moreover, acarbose appeared to inhibit development of renal, cardiovascular, retinal, and neurological complications in various animal models of diabetes and/or hyperlipidaemia. The latter findings await confirmation in clinical studies.

Consistent with its intestinal site of action, acarbose is minimally (<2%) absorbed in unchanged form following oral administration to healthy volunteers. However, it is rapidly and extensively metabolised by intestinal digestive enzymes, and absorption of metabolites formed in the gut yields a biphasic pattern of absorption in studies with radiolabelled acarbose, with separate peaks at 1 to 2 and 6 to 24 hours. Administration of acarbose 300mg 3 times daily for 90 days to healthy volunteers did not result in accumulation.

Acarbose has a small volume of distribution (0.32 L/kg) and was minimally bound to animal plasma proteins at concentrations ≥ 1 μg/L, and 98% bound at 0.008 μg/L. Acarbose and/or its metabolites were secreted into breast milk and penetrated across the placental barrier in rats.

Approximately 35% of an orally administered dose of acarbose is excreted in the urine, virtually all in metabolised form, and approximately 50% in the faeces. The total body clearance of acarbose was around 600 L/h and values of up to 39.5 hours have been reported for the terminal elimination half-life.

Therapeutic Use

In noncomparative and placebo-controlled studies of 2 to 12 months’ duration, acarbose generally improved metabolic control in patients with NIDDM, whether used with diet alone, or with other antidiabetic agents, including sulphonylureas, biguanides or insulin. Postprandial plasma glucose levels were lowered by approximately 2 to 3 mmol/L and glycosylated haemoglobin levels were also decreased. Fasting plasma glucose and triglyceride levels, and insulin requirements, were also occasionally decreased. Acarbose was not effective in some patients, possibly reflecting low dosages used and/or severe carbohydrate restrictions in some instances, or lack of sensitivity of intestinal α-amylases to acarbose.

Acarbose tended to be slightly less effective than sulphonylureas and biguanides, particularly with regard to effects on fasting plasma glucose, but was at least as effective as guar gum in 1 study.

Acarbose has been less well studied in patients with IDDM, but improved glycaemic control, as evidenced by improved daily blood glucose profiles and decreased glycosylated haemoglobin levels, and frequently, decreased insulin requirements. It may also lower the risk of late hypoglycaemic episodes (those occurring several hours after a meal) in patients with IDDM.

Data from preliminary studies indicated that acarbose might be useful in patients with reactive hypoglycaemia, dumping syndrome and types IIb or IV hyperlipidaemia, but to date no large-scale studies appear to have been performed in these indications.

Tolerability

Gastrointestinal disturbances such as flatulence, abdominal distension, diarrhoea and borborygmus, caused by fermentation of unabsorbed carbohydrate in the bowel, are the most common adverse effects associated with acarbose therapy and may occur in up to two-thirds of patients. These symptoms generally improve with continued treatment, and may be minimised by initiating therapy at a low dosage and adherence to diet. The tolerability of acarbose in children aged 5 to 16 years is similar to that in adults.

Systemic adverse effects are rare during acarbose therapy. However, analysis of data from phase III US studies indicated that anaemia and elevated transaminase levels were significantly more common in acarbose, than in placebo recipients, occurring in 3.8 and 1.1% of patients, respectively.

Acarbose was reported to decrease both peak concentrations and area under the concentration-time curve of metformin by 35% when the 2 drugs were given concurrently to healthy volunteers.

Dosage and Administration

The recommended starting dose of acarbose for patients with NIDDM is 50mg 3 times daily, taken before meals, which may be increased to 100mg 3 times daily after 6 to 8 weeks if necessary, and subsequently to a maximum of 200mg 3 times daily if required. Dosages used in patients with IDDM in clinical trials were similar to those used in NIDDM. Patients receiving the maximum dose should be monitored closely for elevation of serum transaminase levels, preferably at monthly intervals, for the first 6 months of treatment. Contraindications to acarbose use include inflammatory bowel disease, partial intestinal obstruction or predisposition to intestinal obstruction, chronic intestinal disease associated with marked disorders of absorption or digestion, conditions which might be exacerbated by increased intestinal gas formation (such as hernias), and impaired hepatic function. Additionally, acarbose has not been studied in patients with severe renal impairment.

As acarbose may potentiate the hypoglycaemic effects of insulin and sulphonylureas, dosages of these agents may require adjustment when acarbose is administered concurrently. If hypoglycaemia occurs, patients should take glucose rather than carbohydrate foods. The effects of acarbose may be reduced by concomitant administration of intestinal adsorbents such as charcoal, and digestive enzyme preparations such as amylase or pancreatin, and enhanced by concomitant administration of neomycin or cholestyramine.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahr HJ, Boberg M, Krause HP, Maul W, Müller FO, et al. Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and excretion after single administration of [14C] acarbose to rats, dogs and man. Arzneimittel-Forschung 39: 1254–1260, 1989aPubMedGoogle Scholar
  2. Ahr HJ, Krause HP, Siefert HM, Steinke W, Weber H. Pharmacokinetics of acarbose. Part II: Distribution to and elimination from tissues and organs following single or repeated administration of [14C] acarbose to rats and dogs. Arzneimittel-Forschung 39: 1261–1267, 1989bPubMedGoogle Scholar
  3. Anon. Acarbose prescribing information, UK, 1993Google Scholar
  4. Austenat E. Recent therapy studies with acarbose in type I diabetics. Endokrinologie und Stoffwechsel 12: 19–24, 1991Google Scholar
  5. Akazawa Y, Koide M, Oishi M, Azuma T, Tashiro S. Clinical usefulness of acarbose and fiber in the treatment of diabetes mellitus. Therapeutics 36: 848–849, 870-875, 1982Google Scholar
  6. Aubell R, Boehme K, Berchtold P. One-year acarbose treatment of diabetic out-patients. Multicentre study part II: efficacy. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October 1981, pp 363–366, Excerpta Medica, Amsterdam, 1982Google Scholar
  7. Axen KV, Sclafani A. Acarbose decreases insulin resistance in a rat model of NIDDM. Diabetes 39 (Suppl. 1): 49A, 1990 (abstract)Google Scholar
  8. Bartram H-P, Scheppach W, Heid C, Fabian C, Kasper H. Effect of starch malabsorption on fecal bile acids and neutral sterols in humans: possible implications for colonic carcinogenesis. Cancer Research 51: 4238–4242, 1991PubMedGoogle Scholar
  9. Boberg M, Kurz J, Ploschke HJ, Schmitt P, Scholl H, et al. Isolation and structural elucidation of biotransformation products from acarbose. Arzneimittel-Forschung 40: 555–563, 1990PubMedGoogle Scholar
  10. Buchanan DR, Collier A, Rodrigues E, Millar AM, Gray RS, et al. Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes. European Journal of Clinical Pharmacology 34: 51–53, 1988PubMedCrossRefGoogle Scholar
  11. Chakrabarti S, Cherian PV, Sima A. The effect of acarbose on diabetes- and age-related basement membrane thickening in retinal capillaries of the BB/W rat. Diabetes Research and Clinical Practice 20: 123–128, 1993PubMedCrossRefGoogle Scholar
  12. Chiasson J-L, Josse RG, Hunt JA, Palmason C, Rodger NW, et al. The effectiveness of acarbose in the treatment of patients with NIDDM. A multi-centre Canadian trial. Submitted for publication 1993.Google Scholar
  13. Chisholm DJ. Diabetes Monitoring; use of glycated haemoglobin and glycated protein assays. Australian Prescriber 14: 59–61, 1991Google Scholar
  14. Clissold SP, Edwards C. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 35: 214–243, 1988PubMedCrossRefGoogle Scholar
  15. Cohen MP, Klepser H. Alpha-glucosidase inhibition prevents increased collagen fluorescence in experimental diabetes. General Pharmacology 22: 607–610, 1991PubMedCrossRefGoogle Scholar
  16. Cohen AM, Rosenmann E. Acarbose treatment and diabetic nephropathy in the Cohen diabetic rat. Hormone and Metabolic Research 22: 511–515, 1990PubMedCrossRefGoogle Scholar
  17. Cohen MP, Klepser H, Wu V-Y. Effect of alpha-glucosidase inhibition on the nonenzymatic glycation of glomerular basement membrane. General Pharmacology 22: 515–519, 1991PubMedCrossRefGoogle Scholar
  18. Coniff RF, Innerfield RJ. A multi-center, double-blind, placebo-controlled study of long-term efficacy and safety of acarbose (Bay g 5421) and SFU in the Rx of NIDDM inadequately controlled by maximal SFU. Abstract. Diabetes 39 (Suppl. 1): 109A, 1990Google Scholar
  19. Couet C, Ulmer M, Hamdaoui M, Bau HM, Debry G. Metabolic effects of acarbose in young healthy men. European Journal of Clinical Nutrition 43: 187–196, 1989PubMedGoogle Scholar
  20. Decarr LB, Velazquez N, Vasselli JR. Acarbose reduces nonenzymatic glycation of low density lipoprotein (GLDL) and improves lipoprotein composition in sucrose-fed diabetic rats. Abstract. Diabetes 40 (Suppl. 1): 270, 1991Google Scholar
  21. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173–194, 1991PubMedCrossRefGoogle Scholar
  22. Deege J, Chantelau E. Alpha-glukosidase inhibition attenuates postprandial plasma glucose response to Coca-Cola™ during insulin-induced hypoglycaemia. In German. Aktuelle Endokrinologie und Stoffwechsel 11: 198–202, 1990Google Scholar
  23. de Leiva A, Piñón P, Tébar J, Escobar-Jimánez F, de Leiva A, de la Calle H, et al. Efficacia clínica y tolerancia de la acarbosa en el tratamiento de pacientes diabéticos no dependientes de la insulina (tipo II). Med Clin (Barcelona) 100: 368–371, 1993Google Scholar
  24. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 329: 977–986, 1993CrossRefGoogle Scholar
  25. Dimitriadis G, Hatziagellaki E, Alexopoulos E, Kordonouri O, Komesidou V, et al. Effects of α-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type 1 diabetes mellitus. Diabetes Care 14: 393–398, 1991PubMedCrossRefGoogle Scholar
  26. Drost H, Hillebrand I, Koschinsky T, Voegtle-Boehringer M, Gries FA. Double-blind cross-over studies on the influence of the glucosidase inhibitor acarbose in type II diabetics. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October, 1981, pp. 330-334, Excerpta Medica, Amsterdam, 1982Google Scholar
  27. Ebert R, Zarth J, Jakob J, Creutzfeldt W. Gastric effects of acarbose in type 2 diabetics. European Journal of Clinical Investigation 23 (Suppl. 1): A43, 1993Google Scholar
  28. Escobar-Jiménez F, de Leiva A, Piñón P, Soler J, Tebar J, et al. Efficacia clínica y tolerancia de la acarbosa en el tratamiento de pacientes diabéticos dependientes de la insulina (tipo 1). Medicina Clinica (Barcelona) 100: 488–491, 1993Google Scholar
  29. Friedman JE, de Venté JE, Peterson RG, Dohm GL. Altered expression of muscle glucose transporter GLUT-4 in diabetic fatty Zucker rats (ZDF/Drt-fa). American Journal of Physiology 261: E782–E788, 1991PubMedGoogle Scholar
  30. Fölsch UR, Lembcke B, Ebert R, Caspary WF, Creutzfeldt W. Sucrose tolerance during treatment with acarbose and/or metronidazole. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October, 1981, pp. 97–106, Exerpta Medica, Amsterdam, 1982Google Scholar
  31. Füessl HS, Adrian TE, Uttenthal LO, Bloom SR. Peptide YY in diabetics treated chronically with an intestinal glucosidase inhibitor. Klinische Wochenshrift 66: 985–989, 1988CrossRefGoogle Scholar
  32. Gérard J, Luyckx AS, Lefebvre PJ. Acarbose in reactive hypoglycaemia: a double-blind study. International Journal of Clinical Pharmacology, Therapy and Toxicology 22: 25–31, 1984aGoogle Scholar
  33. Gérard J, Lefèbvre PJ, Luyckx AS. Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics. European Journal of Clinical Pharmacology 27: 233–236, 1984bPubMedCrossRefGoogle Scholar
  34. Gil E, Guardiola E. Efecto de la acarbosa sobre la glucemia y la secreción de hormonas pancreáticas inducida por comidas habituales en España. Revista Clinica Española 191: 416–421, 1992PubMedGoogle Scholar
  35. Gómez-Pérez FJ, Violante R, Sánchez-Arriaga LF, Wong B, Rull JA. Eficacia y tolerancia de acarbose en pacientes diabéticos no dependientes de insulina. Revista de Investigacíon Clinica 44: 77–83, 1992PubMedGoogle Scholar
  36. Goto Y, Toyoda T, Oikawa S, Moruhama Y, Tamura M, et al. Long-term administration of BAY g 5421 (acarbose) in NIDDM [Translated into English from Japanese.] Yakuri to Chiryo 17: 387–401, 1989aGoogle Scholar
  37. Goto Y, Nakagawa S, Goto Y, Ikeda Y, Hosoya N, et al. Utility of BAY g 5421 (acarbose) on NIDDM, multicentre open study [Translated into English from Japanese.] Kiso to Rinsho 23: 219–239, 1989bGoogle Scholar
  38. Goto Y, Nakagawa S, Goto Y, Hosoya Y, Orishige H et al. Clinical utility of BAY g 5421 (acarbose) on NIDDM. Multicentre double-blind comparative study [Translated into English from Japanese.] Igaku no Ayumi 149: 591–618, 1989cGoogle Scholar
  39. Groop P-H, Groop L, Toetterman KJ, Fyhrquist F. Effects of acarbose on the relationship between changes in GIP and insulin responses to meals in normal subjects. Acta Endocrinologica 112: 361–366, 1986PubMedGoogle Scholar
  40. Groot PHE, van Stiphout WAH, Krauss XH, Jansen H, van Tol A, et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arteriosclerosis and Thrombosis 11: 653–662, 1991PubMedCrossRefGoogle Scholar
  41. Hamada H, Iida R, Mitsuzono T. Effects of acarbose in combination with tolbutamide or insulin on normal and diabetic rats. In Japanese. Yakuri to Chiryo 17: 29–44, 1989aGoogle Scholar
  42. Hamada H, Iida R, Ishimura K. Effect of acarbose on diabetes in KK mice. In Japanese. Yakuri to Chiryo 17: 17–25, 1989bGoogle Scholar
  43. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 14: 732–737, 1991PubMedCrossRefGoogle Scholar
  44. Hasche H, Ulm K, Mehnert H. Ambulant additive therapy with acarbose by badly regulated NIDDs. Abstracts of the 12th Congress of the International Diabetes Federation, Madrid, September, 1985, p 227, Elsevier, Amsterdam, 1985Google Scholar
  45. Hayakawa T, Kondo T, Okumura N, Nagai K, Shibata T, et al. Enteroglucagon release in disaccharide malabsorption induced by intestinal α-glucosidase inhibition. American Journal of Gastroenterology 84: 523–526, 1989PubMedGoogle Scholar
  46. Hiele M, Ghoos Y, Rutgeerts P, Vantrappen G. Effects of acarbose on starch hydrolysis. Study in healthy subjects, ileostomy patients, and in vitro. Digestive Diseases and Sciences 37: 1057–1064, 1992PubMedCrossRefGoogle Scholar
  47. Hillebrand I, Boehme K. Clinical studies on acarbose during 5 years. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October 1981, pp 445–450, Excerpta Medica, Amsterdam, 1982Google Scholar
  48. Hillebrand I, Englert R. Efficacy and tolerability of a 12-week treatment with acarbose (BAY g 5421), miglitol (BAY m 1099) and glibenclamid. Diabetes 26: 134A, 1987Google Scholar
  49. Hillebrand I, Graefe KH, Bischoff H, Frank G, Raemsche KD, et al. Serum digoxin and propranolol levels during acarbose treatment. Diabetologia 21:282, 1981Google Scholar
  50. Hoffmann J. Acarbose and glibenclamid in type-II-diabetes. A comparative study on efficacy and side effects. In German. Münchener Medizinische Wochenschrift 132: 487–490, 1990Google Scholar
  51. Hollander P. Safety profile of acarbose, an a-glucosidase inhibitor. Drugs 44 (Suppl. 2): 47–53, 1992PubMedCrossRefGoogle Scholar
  52. Hollander P, Coniff RF. Two multicenter, double-blind, placebo-controlled studies of efficacy and safety of acarbose treatment of type I diabetes. Diabetes 40 (Suppl. 1): 307A, 1991Google Scholar
  53. Hotta N, Kakuta H, Koh N, Sakakibara F, Haga T, et al. The effect of acarbose on blood glucose profiles of type 2 diabetic patients receiving insulin therapy. Diabetic Medicine 10: 355–358, 1993aPubMedCrossRefGoogle Scholar
  54. Hotta N, Kakuta H, Sano T, Matsumae H, Yamada H, et al. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diabetic Medicine 10: 134–138, 1993bPubMedCrossRefGoogle Scholar
  55. Innerfield RJ, Coniff RF. A multi-center, double-blind, placebo-controlled study of the long-term efficacy and safety of acarbose (Bay g 5421) in the Rx of obese patients with NIDDM Rxed by diet alone. Abstract. Diabetes 39 (Suppl. 1): 211A, 1990Google Scholar
  56. Jenkins DJA, Taylor RH. Acarbose: dosage and interaction with sugars, starch and fibre. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October, 1981, pp. 86–96, Exerpta Medica, Amsterdam, 1982Google Scholar
  57. Jenkins DJA, Taylor RH, Goff DV, Fielden H, Misiewicz JJ, et al. Scope and specificity of acarbose in slowing carbohydrate absorption in man. Diabetes 30: 951–954, 1981PubMedCrossRefGoogle Scholar
  58. Jenkins DJA, Taylor RH, Nineham R, Goff DV, Bloom SR, et al. Manipulation of gut hormone response to food by soluble fiber and a-glucosidase inhibition. American Journal of Gastroenterology 83: 393–397, 1988PubMedGoogle Scholar
  59. Johansen K. Acarbose treatment of sulphonylurea-treated non-insulin dependent diabetics-a double-blind crossover comparison of an a-glucosidase inhibitor with metformin. Diabete et Metabolisme 10: 219–223, 1984PubMedGoogle Scholar
  60. Joubert PH, Venter HL, Foukaridis GN. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism? British Journal of Clinical Pharmacology 30: 391–396, 1990PubMedPubMedCentralCrossRefGoogle Scholar
  61. Katovich MJ, Meldrum MJ, Vasselli JR. Beneficial effects of dietary acarbose in the streptozotocin-induced diabetic rat. Metabolism 40: 1275–1282, 1991PubMedCrossRefGoogle Scholar
  62. Kritchevsky D, Tepper SA, Davidson LM, Klurfeld DM. Influence of acarbose (a glucosidase inhibitor) on experimental atherosclerosis in the rabbit. Artery 17: 170–175, 1990PubMedGoogle Scholar
  63. Ladas SD, Frydas A, Papadopoulos A, Raptis SA. Effects of α-glucosidase inhibitors on mouth to caecum transit time in humans. Gut 33: 1246–1248,1992PubMedPubMedCentralCrossRefGoogle Scholar
  64. Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ, Reaven GM. Acarbose treatment of non-insulin-dependent diabetes mellitus. Archives of Internal Medicine 144: 345–347, 1984PubMedCrossRefGoogle Scholar
  65. Lee SM. The effect of chronic alpha-glucosidase inhibition on diabetic nephropathy in the db/db mouse. Diabetes 31: 249–254, 1982PubMedCrossRefGoogle Scholar
  66. Le Marchand-Brustel Y, Rochet N, Grémeaux T, Marot I, van Obberghen E. Effect of an α-glycosidase inhibitor on experimentally-induced obesity in mice. Diabetologia 33: 24–30, 1990PubMedCrossRefGoogle Scholar
  67. Leonhardt W, Hanefeld M, Fischer S, Schulze J, Spengler M. Beneficial effects on serum lipids in noninsulin-dependent diabetics by acarbose treatment. Arzneimittel Forschung 41: 735–738, 1991PubMedGoogle Scholar
  68. Maggio CA, Vasselli JR. Satiety in the obese Zucker rat: effects of carbohydrate type and acarbose (Bay g 5421). Physiology and Behaviour 46: 557–560, 1989CrossRefGoogle Scholar
  69. Marena S, Tagliaferro V, Cavallero G, Pagani A, Montegrosso G, et al. Double-blind crossover study of acarbose in type 1 diabetic patients. Diabetic Medicine 8: 674–678, 1991PubMedCrossRefGoogle Scholar
  70. Maruhama Y, Goto Y. Clinical application of a glucoside-hydrolase inhibitor (Bay g 5421) to patients with hyperlipidemia and maturity onset type diabetes mellitus. Tohoku Journal of Experimental Medicine 130: 243–252, 1980CrossRefGoogle Scholar
  71. Maruhama Y, Nagasaki A, Kanazawa Y, Hirakawa H, Goto Y, et al. Effects of a glucoside-hydrolase inhibitor (Bay g 5421) on serum lipids, lipoproteins and bile acids, faecal fat and bacterial flora, and intestinal gas production in hyperlipidemic patients. Tohuku Journal of Experimental Medicine 132: 453–462, 1980CrossRefGoogle Scholar
  72. McCulloch DK, Kurtz AB, Tattersall RB. A new approach to the treatment of nocturnal hypoglycaemia using alpha-glucosidase inhibition. Diabetes Care 6: 483–487, 1983PubMedCrossRefGoogle Scholar
  73. Mies R, Spengler M. Efficacy of the glucosidase inhibitor acarbose compared to the sulphonylurea glisepoxid on metabolic control of type 2 (non — insulin-dependent) diabetes. Diabetologia 30: 557A, 1987Google Scholar
  74. Moller DE, Hier JS. Insulin resistance — mechanisms, syndromes and implications. New England Journal of Medicine 325: 938–948, 1991PubMedCrossRefGoogle Scholar
  75. Müller FO, Hillebrand I. Acarbose (BAY g 5421) kinetics in healthy volunteers. Acta Pharmacologica et Toxicologica 59 (Suppl. V): 303, 1986Google Scholar
  76. Nestel PJ, Bazelmans J, Reardon MF, Boston RC. Lower triglyceride production during carbohydrate-rich diets through acarbose, a glucoside hydrolase inhibitor. Diabete et Metabolisme 11: 316–317, 1985PubMedGoogle Scholar
  77. O’Dea K, Turton J. Optimum effectiveness of intestinal α-glucosidase inhibitors: importance of uniform distribution through a meal. American Journal of Clinical Nutrition 41: 511–516, 1985PubMedGoogle Scholar
  78. Petersen K-G. Effects of acarbose in sulphonylurea-treated diabetics in comparison to buformin. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October, 1981, pp. 325–329, Exerpta Medica, Amsterdam, 1982Google Scholar
  79. Patsch JR, Hopferwieser T, Muhlberger V, Knapp E, Braunsteiner H, et al. Postprandial lipemia in patients with coronary artery disease. Circulation 82 (Suppl. III), abstract no. 1129, 1990Google Scholar
  80. Pinquier JL, Pello JY, Rey E, de Lauture D, D’Athis P, et al. Effect of acarbose repeated dosing on antipyrine test in healthy volunteers. In Lefèbvre PJ, Standl E (Eds.) New Aspects in Diabetes. Treatment Strategies with Alpha-Glucosidase Inhibitors, pp 291–294. De Gruyter, Berlin 1992Google Scholar
  81. Pütter J. Studies on the pharmacokinetics of acarbose in humans. In Brodbeck U (Ed.). Enzyme Inhibitors, pp 139–151, Verlag Chemie, Weinheim, 1980.Google Scholar
  82. Pütter J, Keup U, Krause HP, Mueller L. Weber H. Pharmacokinetics of acarbose. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October 1981, pp. 38–48, Excerpta Medica, Amsterdam, 1982Google Scholar
  83. Reaven GM, Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 13 (Suppl. 3): 32–36, 1990PubMedCrossRefGoogle Scholar
  84. Raptis S, Dimitriadis G, Etzrodt H, Kraraiskos C, Hadjidakis D, et al. The effects of acarbose treatment on release of pancreatic and gastrointestinal hormones in man. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October 1981, pp. 210-215, Excerpta Medica, Amsterdam, 1982Google Scholar
  85. Reichard P, Nilsson B-Y, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine 329: 304–309, 1993PubMedCrossRefGoogle Scholar
  86. Richard JL, Rodier M, Monnier L, Orsetti A, Mirouze J. Effect of acarbose on glucose and insulin response to sucrose load in reactive hypoglycaemia. Diabète et Metabolisme 14: 114–118, 1988PubMedGoogle Scholar
  87. Rodier M, Richard JL, Monnier L, Mirouze J. Effect of long term acarbose (Bay g 5421) therapy on metabolic control of non insulin dependent diabetes (type II) mellitus. Diabète et Metabolisme 14: 12–14, 1988PubMedGoogle Scholar
  88. Ruppin H, Hagel J, Feuerbach W, Schutt H, Pichl J, et al. Fate and effects of the α-glucosidase inhibitor acarbose in humans. An intestinal slow-marker perfusion study. Gastroenterology 95: 93–99, 1988PubMedGoogle Scholar
  89. Russell JC, Koeslag DG, Dolphin PJ, Amy RM. Beneficial effects of acarbose in the atherosclerosis-prone JCR: LA-corpulent rat. Metabolism 42: 218–223, 1993PubMedCrossRefGoogle Scholar
  90. Rybka J, Gregorová A, Zmydlena A, Jaron P. Clinical study of acarbose. Drug Investigation 2: 264–267, 1990CrossRefGoogle Scholar
  91. Ryu JE, Howard G, Craven TE, Bond MG, Hagaman AP, et al. Postprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects. Stroke 23: 823–828, 1992PubMedCrossRefGoogle Scholar
  92. Sailer D, Roeder G. Treatment of non-insulin dependent diabetic adults with a new glycoside hydrolase inhibitor (Bay g 5421). Arzneimittel-Forschung 30: 2181–2185, 1980Google Scholar
  93. Sailer D, Gossner L, Schönfuss I. Einfluss von acarbose auf den Spritz-Ess-Abstand beim typ-1-diabetes. Fortschritte der Medizin 110: 479–480, 1992PubMedGoogle Scholar
  94. Sakamoto N, Shibata M, Hotta N, Kakuta H, Tomita A, et al. Clinical study on BAY g 5421 (acarbose) for non-insulin-dependent diabetes mellitus (NIDDM). Yakuri to Chiryo 17: 633–649, 1989Google Scholar
  95. Savage AP, Adrian TE, Carolan G, Chatterjee VK, Polak JM, et al. Effects of peptide YY (PYY) on mouth-caecum intestinal transit and gastric emptying. Gut 28: 166–170, 1987PubMedPubMedCentralCrossRefGoogle Scholar
  96. Scheen AJ, Ferreira Alves de Magalhaes AC, Salvatore T, Lefèbvre PJ. Reduction of metformin acute bioavailability by the alpha-glucosidase inhibitor acarbose in normal man. Abstract. European Journal of Clinical Investigation 23 (Suppl. 1): A43, 1993Google Scholar
  97. Scheppach W, Fabian C, Sachs M, Kasper H. The effect of starch malabsorption on fecal short-chain fatty acid excretion in man. Scandinavian Journal of Gastroenterology 26: 755–759, 1988CrossRefGoogle Scholar
  98. Schöffling K, Petzoldt R, Hillebrand I, Schwedes U. Comparison of metformin and acarbose treatment in non-insulin dependent diabetics (NIDDM): a double-blind cross over study. In Melish J.S., et al. (Eds) Genetic environmental interaction in diabetes mellitus. Proceedings of the Third Symposium on Diabetes Mellitus in Asia and Oceania, Honolulu, February 1981, pp 339-343, Excerpta Medica, Amsterdam, 1982Google Scholar
  99. Shimoyama T, Hori S, Tamura K, Tanida N, Hosomi M, et al. Effects of acarbose on faecal microflora of hyperlipidaemic patients. In Creutzfeldt W. (Ed.) Proceedings of First International Symposium on Acarbose, Montreux, October 1981, pp 123-136, Excerpta Medica, Amsterdam, 1982Google Scholar
  100. Sima AAF, Chakrabarti S. Long-term suppression of postprandial hyperglycaemia with acarbose retards the development of neuropathies in the BBAV-rat. Diabetologia 35: 325–330, 1992PubMedCrossRefGoogle Scholar
  101. Simons LA, Dwyer T, Simons J, Bernstein L, Mock P, et al. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis 65: 181–189, 1987PubMedCrossRefGoogle Scholar
  102. Spengler M, Cagatay M. Evaluation of efficacy and tolerability of acarbose by postmarketing surveillance. Diabetes und Stoffwechsel 1: 218–222, 1992aGoogle Scholar
  103. Spengler M, Cagatay M. Assessment of efficacy and tolerability of acarbose in diabetic patients 5–16 years of age. In Lefebvre PJ, Standl E (Eds.) New Aspects in Diabetes. Treatment Strategies with Alpha-Glucosidase Inhibitors, pp 290–294. De Gruyter, Berlin 1992bGoogle Scholar
  104. Spengler M, Hänsel G, Boehme K. Efficacy of 6 months monotherapy with glucosidase inhibitor acarbose versus sulphonylurea glibenclamide on metabolic control of dietary treated type II diabetics (NIDDM). Hormone and Metabolic Research 26 (Suppl.):50–51, 1992aGoogle Scholar
  105. Spengler M, Hobler H, Cagatay M. Long-term tolerability of acarbose. In Lefèbvre PJ, Standl E (Eds.) New Aspects in Diabetes. Treatment Strategies with Alpha-Glucosidase Inhibitors, pp 286–288. De Gruyter, Berlin 1992bGoogle Scholar
  106. Standl E, Janka HU. High serum insulin concentrations in relation to other cardiovascular risk factors in macrovascular disease of type 2 diabetes. Hormone and Metabolic Research 15 (Suppl.): 46–51, 1985Google Scholar
  107. Stout RW. Insulin and atheroma. 20-year perspective. Diabetes Care 13: 631–654, 1990PubMedCrossRefGoogle Scholar
  108. Taylor RH, Jenkins DJA, Barker HM, Fielden H, Goff DV, et al. Effect of acarbose on the 24-hour blood glucose profile and pattern of carbohydrate absorption. Diabetes Care 5: 92–96, 1982PubMedCrossRefGoogle Scholar
  109. Toeller M. Nutritional recommendations for diabetic patients and treatment with α-glucosidase inhibitors. Drugs 44 (Suppl. 3): 13–20, 1992PubMedCrossRefGoogle Scholar
  110. Tulp OL, Abdollahi A, Stevens C, Schnitzer-Polokoff R. The effects of the intestinal glucosidase inhibitor acarbose on cholesterogenesis in corpulent rats. Biochemical Physiology 100A: 763–768, 1991CrossRefGoogle Scholar
  111. Tuomilehto J. Acarbose monotherapy in the treatment of non-insulin-dependent diabetes mellitus — a review. In Creutzfeldt W. (Ed.) Proceedings of the Second International Symposium on Acarbose, Berlin, 1987, pp 105-116, Springer-Verlag, 1988Google Scholar
  112. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 34: 877–890, 1991CrossRefGoogle Scholar
  113. Uttenthal LO, Ukponmwam OO, Ghiglione M, Bloom SR. Acute and short term effects of intestinal alpha-glucosidase inhibition on gut hormone responses in man. Digestive Diseases and Sciences 32: 139–144, 1987PubMedCrossRefGoogle Scholar
  114. Van Gaal L, De Leeuw I, Branolte J. Mineral and vitamin absorption during acarbose treatment. In Alberti et al. (Eds) 11th Congress of the International Diabetes Federation, Nairobi, November 1982, p 35, Excerpta Medica, Amsterdam, 1982Google Scholar
  115. Van Gaal L, Nobels F, De Leeuw I. Effects of acarbose on carbohydrate metabolism, electrolytes, minerals and vitamins in fairly well-controlled non-insulin-dependent diabetes mellitus. Zeitschrift fur Gastroenterologie 29: 642–644, 1991PubMedGoogle Scholar
  116. Walter-Sack IE, Wolfram G, Zöllner N. Effects of acarbose on serum lipoproteins in healthy individuals during prolonged administration of a fiber-free formula diet. Annals of Nutrition and Metabolism 33: 100–107, 1989PubMedCrossRefGoogle Scholar
  117. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes. Lancet 341: 1306–1309, 22 May 1993PubMedCrossRefGoogle Scholar
  118. William-Olsson T. A-glucosidase inhibition in obesity. Acta Medica Scandinavica 706 (Suppl. 1): 1–39, 1985PubMedGoogle Scholar
  119. William-Olsson T, Krotkiewski M, Sjöström L. Relapse-reducing effects of acarbose after weight reduction in severely obese subjects. Journal of Obesity and Weight Regulation 4: 20–32, 1985Google Scholar
  120. Willms B. Acarbose in non-insulin-dependent diabetes mellitus: combination with sulfonylureas and interaction with diet. In Lefèbvre PJ, Standl E (Eds.) New Aspects in Diabetes. Treatment Strategies with Alpha-Glucosidase Inhibitors, pp 163-176. De Gruyter, Berlin 1992aGoogle Scholar
  121. Willms B. Therapie des typ-II-diabetes-α-glukosidasehemmer (acarbose). Aktuelle Endokrinologie und Stoffwechsel 13: 51–56, 1992bGoogle Scholar
  122. Young JC, Kurowski TG, O’Hare T, Vasselli JR, Ruderman NB. Effect of oral α-glucosidase inhibitor BAY g5421 on glucose uptake in skeletal muscle. Abstract. Diabetes 40 (Suppl. 1): 25A, 1991Google Scholar
  123. Zillikens MC, Swart GR, van den Berg JWO, Wilson JHP. Effects of the glucosidase inhibitor acarbose in patients with liver cirrhosis. Alimentary Pharmacology and Therapeutics. 3: 453–459, 1989PubMedCrossRefGoogle Scholar
  124. Zimmerman BR. Preventing long term complications. Implications for combination therapy with acarbose. Drugs 44 (Suppl. 3): 54–59, 1992PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Julia A. Balfour
    • 1
  • Donna McTavish
    • 1
  1. 1.Adis International LtdMairangi Bay, AucklandNew Zealand

Personalised recommendations